Estriol: Targeted Hormone Therapy for Symptom Relief
| Product dosage: 1 g | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $34.15 | $34.15 (0%) | 🛒 Add to cart |
| 2 | $32.14 | $68.30 $64.29 (6%) | 🛒 Add to cart |
| 3 | $30.47 | $102.46 $91.41 (11%) | 🛒 Add to cart |
| 4 | $29.38 | $136.61 $117.52 (14%) | 🛒 Add to cart |
| 5 | $27.52
Best per tube | $170.76 $137.61 (19%) | 🛒 Add to cart |
Synonyms | |||
Estriol is a bioidentical estrogen hormone primarily indicated for the management of genitourinary symptoms associated with menopause, such as vaginal dryness, itching, burning, and dyspareunia. As a weak estrogen, it offers localized efficacy with a favorable safety profile due to its selective action on estrogen receptors in urogenital tissues. Available in various formulations including creams, gels, and suppositories, estriol provides a tailored approach to hormone therapy, minimizing systemic absorption while effectively restoring vaginal epithelium and alleviating discomfort. It is often preferred in clinical settings where systemic estrogen effects are undesirable or contraindicated.
Features
- Bioidentical molecular structure identical to endogenous human estriol
- Available in topical formulations: cream (0.01% to 0.1%), vaginal gel, suppositories
- Low systemic absorption with primarily local tissue effects
- Minimal impact on endometrial proliferation compared to stronger estrogens
- Typically dosed for short-term or intermittent use
- Compatible with various delivery systems for patient-specific application
Benefits
- Effectively relieves vaginal atrophy, reducing discomfort and pain during intercourse
- Restores normal vaginal pH and flora, decreasing susceptibility to infections
- Provides localized symptom relief without significant systemic hormonal effects
- Low risk of endometrial hyperplasia, often eliminating need for concomitant progestin
- Improves quality of life by addressing intimate health concerns discreetly
- Flexible dosing regimens allow for personalized treatment approaches
Common use
Estriol is predominantly prescribed for the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. It is particularly valuable for patients who experience urogenital symptoms but wish to avoid systemic hormone therapy or have contraindications to stronger estrogens. Clinical applications include management of dyspareunia, vaginal dryness, pruritus, and recurrent urinary tract infections associated with atrophic changes. Some European countries also utilize estriol as part of combination hormone therapy for systemic menopausal symptoms, though this use is less common in North America. Off-label applications may include adjuvant therapy in certain fertility treatments and management of some dermatological conditions.
Dosage and direction
Standard initial dosage for vaginal atrophy is 0.5 mg estriol (approximately 0.5 g of 0.1% cream) administered intravaginally once daily for 2-3 weeks, followed by a maintenance dose of 0.5 mg twice weekly. Application should occur at bedtime to minimize leakage and enhance absorption. For cream formulations: use the supplied applicator to measure the prescribed amount, insert intravaginally while lying down, and cleanse applicator after each use. Gel and suppository formulations follow similar frequency patterns with product-specific administration instructions. Treatment duration is typically evaluated every 3-6 months, with many patients achieving sustained benefit on maintenance dosing.
Precautions
Patients should undergo thorough gynecological assessment before initiation, including breast examination and evaluation of personal cancer risk. Regular monitoring of endometrial status is recommended, though the risk of stimulation is low with estriol monotherapy. Use with caution in patients with conditions that might be influenced by fluid retention (e.g., cardiac or renal dysfunction, asthma, epilepsy, migraine). Topical application may potentially transfer to sexual partners; advise barrier contraception if this is a concern. Discontinuation should be gradual rather than abrupt to prevent recurrence of symptoms. Patients should be informed that estriol does not provide contraception and may not prevent bone loss associated with menopause.
Contraindications
Known or suspected pregnancy; nursing mothers; undiagnosed abnormal genital bleeding; known or suspected estrogen-dependent neoplasia; active or history of thromboembolic disorders; severe hepatic dysfunction; hypersensitivity to estriol or any product components; porphyria.
Possible side effect
Most side effects are local and transient: vaginal irritation, itching, burning sensation, or discharge. Systemic effects are uncommon but may include breast tenderness, headache, nausea, fluid retention, or mood changes. Rare reports of abdominal cramps, dizziness, or skin reactions. Long-term use, even at low doses, may potentially increase risk of endometrial changes; however, this is significantly lower than with stronger estrogens.
Drug interaction
May reduce effectiveness of tamoxifen; monitor patients receiving both medications. Hepatic enzyme inducers (e.g., rifampicin, phenytoin, carbamazepine, St. John’s wort) may increase estrogen metabolism, reducing efficacy. Estriol may alter glucose tolerance, necessitating adjustment of antidiabetic medications. Potential interaction with corticosteroids due to fluid retention effects. Theoretical interactions with thyroid hormone replacement therapy requiring monitoring of thyroid function.
Missed dose
Apply the missed dose as soon as remembered, unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed application. Resume regular dosing schedule. For twice-weekly maintenance regimens, if a dose is missed, apply it when remembered and then resume the regular schedule. Consistent application is important for initial therapeutic effect, but occasional missed doses during maintenance therapy are unlikely to significantly impact efficacy.
Overdose
Acute overdose with topical estriol is unlikely due to limited systemic absorption. Single large doses may cause nausea, vomiting, or breast tenderness. No specific antidote exists; treatment should be symptomatic and supportive. Vaginal irrigation may be considered if recent application. Medical attention should be sought if concerning symptoms develop. Chronic excessive use may lead to increased systemic absorption and estrogenic effects requiring dosage reduction or temporary discontinuation.
Storage
Store at room temperature (15-30°C/59-86°F); avoid freezing. Keep tube tightly closed and away from direct light. Do not store in bathroom where moisture and temperature fluctuations may degrade the product. Keep out of reach of children and pets. Discard any product that has changed color, consistency, or odor. Note expiration date on packaging; do not use beyond this date.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Estriol is a prescription medication requiring proper medical supervision. Individual response may vary based on health status, concomitant medications, and other factors. Patients should consult their healthcare provider for personalized medical advice, diagnosis, and treatment. Never initiate, modify, or discontinue medication without professional guidance.
Reviews
Clinical studies demonstrate estriol’s efficacy in improving vaginal health indices (maturation value, pH, elasticity) with significant symptom relief reported by 70-85% of users. Patients appreciate the localized action with minimal systemic side effects compared to conventional estrogen therapy. Healthcare providers value its favorable safety profile, particularly in older patients or those with contraindications to systemic estrogen. Long-term satisfaction rates remain high when used according to prescribed regimens, with many patients reporting restored comfort and improved intimate relationships. Ongoing research continues to explore potential expanded applications in menopausal health management.